From Medscape Gastroenterology

Coverage from the

European Crohn's and Colitis Organisation (ECCO) 2025 Congress

February 19 - 22, 2025; Berlin, Germany

February 19 - 22, 2025 Berlin, Germany

Conference News

ECCO 2025 Vedolizumab Beats Infliximab as Second-Line UC Therapy
Medscape Medical News, March 6, 2025
ECCO 2025 Metabolomic Profiles Predict IBD up to 10 Years Before Onset
Medscape Medical News, March 4, 2025
ECC0 2025 Subcutaneous Guselkumab Proves Efficacious for IBD
Medscape Medical News, February 28, 2025
ECC0 2025 Anxiety, Depression Linked to IBD Flare
Medscape Medical News, February 28, 2025
ECC0 2025 Machine Learning Identifies Gut Biomarkers for IBD
Medscape Medical News, February 27, 2025
ECC0 2025 New IL-7 Antagonist Lusvertikimab Shows UC Efficacy
Medscape Medical News, February 26, 2025

ECC0 2025 Virtual Chromoendoscopy Better at Neoplasia Detection in IBD
Medscape Medical News, February 25, 2025
ECC0 2025 AI Improves Lesion Detection in IBD Over Standard Methods
Medscape Medical News, February 24, 2025
ECC0 2025 Antibody Profiles Predict IBD Up To 10 Years Before Onset
Medscape Medical News, February 24, 2025
ECC0 2025 New Biomarkers Identified for Treatment Response in IBD
Medscape Medical News, February 23, 2025
ECCO 2025 Not All Plant-Based Diets Are Equal in IBD Risk Mitigation
Medscape Medical News, February 21, 2025

Medscape Gastroenterology©

Popular News From ECCO 2024

Capsule Endoscopy–Guided Treatment Reduces Flares in Crohn's Patients with Crohn's disease who are considered high-risk as determined by capsule endoscopy but are in clinical remission benefit from a treat-to-target strategy, a new study shows.
Medscape Medical News, Feb 22, 2024
Risankizumab in CD: Outcomes Remain Stable up to 3 Years Long-term data show clinical remission and endoscopic response rates are maintained and even improve over time in patients with moderate to severe Crohn's disease, according to a new study.
Medscape Medical News, Feb 23, 2024
Novel Biotherapeutic to Be Tested in Ulcerative Colitis An investigational combination of eight strains of bacteria known collectively as MB310 — a live biotherapeutic product — is due to start its first clinical trial in ulcerative colitis.
Medscape Medical News, Feb 26, 2024

Previous Coverage

Related Resources

Inflammatory Bowel Disease

All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.